TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02335411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral tablets
Study: NCT04165174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terepril monoclonal antibody; Apatinib
Description: Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 6-10Gy/F,5-8F
Study: NCT03041012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: 5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
Study: NCT02516449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Description: The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?
Study: NCT04480359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bawei Shenqi Pill
Description: 5.1g, once a day, 3month, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bawei Shenqi Pill placebo
Description: 5.1g, once a day, 3month, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: 7.5mg, once a day, 3 month, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meloxicam
Description: 7.5mg, once a day, 3 month, oral
Study: NCT00960869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-Aspirin 325 mg
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Study: NCT03240042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasotracheal intubation
Description: The participants either receive intubation via nasal route.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: orotracheal intubation
Description: The participants either receive intubation via oral route.
Study: NCT03288636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01518374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: 370 MBq (10 mCi)
Study: NCT01968772

Intervention type: OTHER
Group type: OTHER
Intervention: Transdermal Magnesium Chloride
Description: Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
Study: NCT04084860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: CI-581a during weeks 1 and 6 at 0.71 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: CI-581a during weeks 1 and 6 at 0.71 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: CI-581b during weeks 1 and 6 at 0.0125 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: CI-581b during weeks 1 and 6 at 0.0125 mg/kg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBRP
Description: MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBRP
Description: MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
Study: NCT04113187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Description: 40 mg twice a day (morning and evening), per os, during three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os, twice a day (morning and evening) during three months
Study: NCT00673699

Intervention type: PROCEDURE
Intervention: Gastric mucosal biopsy
Description: Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
Study: NCT02950727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 bicortical screws
Description: after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: adjustable plate and 2 bicortical screws
Description: after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
Study: NCT03041012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: 5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117
Description: 30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117
Description: 30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy
Study: NCT04037592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active standardized iTBS-DMPFC
Description: Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active high-dosage iTBS-DMPFC
Description: Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC
Description: Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
Study: NCT00623844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
Study: NCT03057197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new caudal injection technique
Description: new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
Study: NCT02027766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calf muscle stretching
Study: NCT00975793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Therapy (EGDT)
Description: Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
Study: NCT03580746

Intervention type: PROCEDURE
Intervention: Taping and posteromedial release

Intervention type: PROCEDURE
Intervention: Ponseti
Study: NCT03647995

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiolife by Green Made (Pharma M)
Description: A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
Study: NCT03041012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy
Study: NCT03143270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Transarterial Chemoembolization
Description: Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
Study: NCT02054442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT01330472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR tablets 3 mg (sourced from Caugus)
Description: Tablets, 3 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanax XR tablets 3 mg (sourced from Barceloneta)
Description: Tablets, 3 mg, single dose
Study: NCT02362464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Description: dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
Study: NCT02392572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO
Study: NCT03522688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
Study: NCT01862224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: JNJ-38518168 30 mg once daily, Week 0 to Week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-38518168
Description: JNJ-38518168 30 mg once daily, Week 0 to Week 52.
Study: NCT03924570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPASS
Description: IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
Study: NCT03143270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Transarterial Chemoembolization
Description: Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Transarterial Chemoembolization
Description: Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
Study: NCT01862224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily (Week 0 to Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
Study: NCT03655704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apabetalone
Description: A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
Study: NCT00810654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease
Description: 160 PPU daily for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03082040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based breathing training
Description: The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
Study: NCT00329771

Intervention type: OTHER
Intervention: No intervention: We are testing for the presence of allodynia
Description: We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
Study: NCT03082040

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: home-based breathing training
Description: The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
Study: NCT03195270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FDG
Description: 10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MRI hybrid scanner used as diagnostic device
Study: NCT00927277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser
Description: The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Erchonia(R) LipoLASER PL
Study: NCT03722732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy either laparoscopically or open will be done
Study: NCT03044691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ResearchACTS software
Description: screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
Study: NCT01708369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
Study: NCT01259219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobutin
Description: Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder.
Study: NCT04727099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay Laser System
Description: The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay Laser System
Description: The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
Study: NCT04449822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgery
Description: Surgical decompression with colostomy with or without resection and eventual re-anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic stenting
Description: The colonic stent placement to relieve the colonic obstruction.
Study: NCT01708369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Orange juice administered 15 minutes before subjects take oseltamivir or aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
Study: NCT03958305

Intervention type: PROCEDURE
Intervention: RADICAL HYSTERECTOMY
Description: Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.

Intervention type: PROCEDURE
Intervention: RADICAL HYSTERECTOMY
Description: Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
Study: NCT02379975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Periodontal Therapy
Study: NCT01708369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 150 mg orally
Study: NCT02379975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical Periodontal Therapy
Study: NCT03374722

Intervention type: DRUG
Intervention: Opioids
Description: Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased